These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 15001610

  • 1. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J.
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
    [Abstract] [Full Text] [Related]

  • 2. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP, Yu XB, Luo L, Han Y, Qiu ZF, Zuo LY, Li YL, Yu W, Li TS.
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
    [Abstract] [Full Text] [Related]

  • 3. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
    Fernández-Rivera J, García R, Lozano F, Macías J, García-García JA, Mira JA, Corzo JE, Gómez-Mateos J, Rueda A, Sánchez-Burson J, Pineda JA.
    HIV Clin Trials; 2003 Aug; 4(5):337-46. PubMed ID: 14583850
    [Abstract] [Full Text] [Related]

  • 4. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
    Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):24-8. PubMed ID: 14715822
    [Abstract] [Full Text] [Related]

  • 5. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G, Spanu A, Solinas P, Babudieri S, Calia GM, Lovigu C, Mannazzu M, Nuvoli S, Piras B, Bagella P, Mura MS, Madeddu G.
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [Abstract] [Full Text] [Related]

  • 6. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
    Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, Mercié P, Morlat P, Thiébaut R, Dabis F, Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
    AIDS; 2008 Jan 30; 22(3):395-402. PubMed ID: 18195566
    [Abstract] [Full Text] [Related]

  • 7. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2004 Mar 30; 48(1):39-48. PubMed ID: 15195003
    [Abstract] [Full Text] [Related]

  • 8. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB, Xie J, Han Y, Qiu ZF, Li YL, Song XJ, Yu W, Li TS.
    Zhonghua Yi Xue Za Zhi; 2012 May 08; 92(17):1155-8. PubMed ID: 22883000
    [Abstract] [Full Text] [Related]

  • 9. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 10. Reduced bone mineral density among HIV-infected patients in Taiwan: prevalence and associated factors.
    Tsai MS, Hung CC, Liu WC, Chen KL, Chen MY, Hsieh SM, Sheng WH, Sun HY, Shih TT.
    J Microbiol Immunol Infect; 2014 Apr 01; 47(2):109-15. PubMed ID: 23073318
    [Abstract] [Full Text] [Related]

  • 11. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.
    Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK.
    J Clin Endocrinol Metab; 2001 May 01; 86(5):2020-6. PubMed ID: 11344201
    [Abstract] [Full Text] [Related]

  • 12. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population.
    Pinto Neto LF, Ragi-Eis S, Vieira NF, Soprani M, Neves MB, Ribeiro-Rodrigues R, Miranda AE.
    J Clin Densitom; 2011 May 01; 14(4):434-9. PubMed ID: 22051092
    [Abstract] [Full Text] [Related]

  • 13. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2012 May 01; 76(5):643-8. PubMed ID: 22040002
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.
    Muhammad S, Sani MU, Okeahialam BN.
    Ann Afr Med; 2013 May 01; 12(1):24-8. PubMed ID: 23480991
    [Abstract] [Full Text] [Related]

  • 15. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
    Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A.
    AIDS; 2001 Sep 28; 15(14):1823-9. PubMed ID: 11579244
    [Abstract] [Full Text] [Related]

  • 16. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2007 Aug 28; 67(2):270-5. PubMed ID: 17547686
    [Abstract] [Full Text] [Related]

  • 17. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
    Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Mannazzu M, Falchi A, Sanna D, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2009 Jun 28; 53(3):290-301. PubMed ID: 18596668
    [Abstract] [Full Text] [Related]

  • 18. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
    Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S.
    Osteoporos Int; 2018 Mar 28; 29(3):595-613. PubMed ID: 29159533
    [Abstract] [Full Text] [Related]

  • 19. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.
    HIV Med; 2006 Jan 28; 7(1):38-45. PubMed ID: 16313291
    [Abstract] [Full Text] [Related]

  • 20. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, Hasson H, Danise A, Guffanti M, Lazzarin A, Rubinacci A.
    HIV Med; 2005 May 28; 6(3):145-50. PubMed ID: 15876279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.